SCHEMBL21872995

SCHEMBL21872995

Cc1nc(-c2cnc(NC(C)C)[nH]c2=O)ccc1C(=O)c1c[nH]c2ncccc12

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ CSF1R P07333 5/20 0.48
▸ PDGFRA P16234 3/20 0.48
▸ PDGFRB P09619 1/20 0.48
▸ KDR P35968 2/20 0.43
▸ MAP2K1 Q02750 1/20 0.40
▸ CDK2 P24941 6/20 0.36
▸ CCNE1 P24864 5/20 0.36
▸ CDC7 O00311 2/20 0.36
▸ DBF4 Q9UBU7 2/20 0.36
▸ KDM4E B2RXH2 1/20 0.36
▸ ALDH1A1 P00352 1/20 0.36
▸ BRAF P15056 1/20 0.35
▸ FLT3 P36888 1/20 0.34
▸ ROCK1 Q13464 1/20 0.34
▸ DYRK1A Q13627 1/20 0.34
▸ ADORA2A P29274 1/20 0.34
▸ CCNT1 O60563 1/20 0.34
▸ CCNA2 P20248 1/20 0.34
▸ CDK9 P50750 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21977192 0.83 CSF1R (0.43) CSF1RPDGFRAPDGFRBKDRMAP2K1
SCHEMBL21873140 0.81 GPR84 (0.46) CSF1RPDGFRAPDGFRBKDRCDK2
SCHEMBL21872991 0.81 MAP2K1 (0.43) KDRMAP2K1CDK2CCNE1CDC7
SCHEMBL21965137 0.79 CSF1R (0.46) CSF1RPDGFRAPDGFRBKDRFLT3
SCHEMBL21873044 0.74 CDK2 (0.39) KDRMAP2K1CDK2CCNE1CDC7
SCHEMBL21873065 0.73 CSF1R (0.47) CSF1RPDGFRAPDGFRBKDRCDK2
SCHEMBL28337392 0.72 CSF1R (0.45) CSF1RPDGFRAPDGFRBKDRKDM4E
SCHEMBL21873156 0.71 CSF1R (0.52) CSF1RPDGFRAPDGFRBKDRCDC7
SCHEMBL21873079 0.71 CSF1R (0.43) CSF1RPDGFRAPDGFRBKDRMAP2K1
SCHEMBL21873024 0.70 CSF1R (0.44) CSF1RPDGFRAPDGFRBKDRKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11180495-B2 Nitrogen heteroaryl derivative having CSF1R inhibitory activity, and preparation method therefor and application thereof ABBISKO THERAPEUTICS CO., LTD. (CN) 2021-11-23 — — US disclosed
US-11180495-B2 Nitrogen heteroaryl derivative having CSF1R inhibitory activity, and preparation method therefor and application thereof ABBISKO THERAPEUTICS CO., LTD. (CN) 2021-11-23 — — US disclosed
US-20200140431-A1 NITROGEN HETEROARYL DERIVATIVE HAVING CSF1R INHIBITORY ACTIVITY, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF ABBISKO THERAPEUTICS CO., LTD. (CN) 2020-05-07 — — US disclosed
US-20200140431-A1 NITROGEN HETEROARYL DERIVATIVE HAVING CSF1R INHIBITORY ACTIVITY, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF ABBISKO THERAPEUTICS CO., LTD. (CN) 2020-05-07 — — US disclosed
EP-3643715-A1 NITROGEN HETEROARYL DERIVATIVE HAVING CSF1R INHIBITORY ACTIVITY, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF Abbisko Therapeutics Co., Ltd. (CN) 2020-04-29 — — EP disclosed
EP-3643715-A1 NITROGEN HETEROARYL DERIVATIVE HAVING CSF1R INHIBITORY ACTIVITY, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF Abbisko Therapeutics Co., Ltd. (CN) 2020-04-29 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200140431-A1 NITROGEN HETEROARYL DERIVATIVE HAVING CSF1R INHIBITORY ACTIVITY, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF CSF1R, CSF3R, FSHR CSF1R 1/4885PDGFRA 229/4885PDGFRB 149/4885
US-11180495-B2 Nitrogen heteroaryl derivative having CSF1R inhibitory activity, and preparation method therefor and application thereof CSF1R, CSF3R, FSHR CSF1R 1/4885PDGFRA 229/4885PDGFRB 149/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback